AstraZeneca says ENHERTU achieved 61.6% progression-free survival rate in study
PremiumThe FlyAstraZeneca says ENHERTU achieved 61.6% progression-free survival rate in study
5d ago
Deutsche downgrades AstraZeneca to Sell on challenging risk/reward
Premium
The Fly
Deutsche downgrades AstraZeneca to Sell on challenging risk/reward
6d ago
AstraZeneca downgraded to Sell from Hold at Deutsche Bank
Premium
The Fly
AstraZeneca downgraded to Sell from Hold at Deutsche Bank
6d ago
AstraZeneca Shares Fall on Lung Cancer Drug Trial’s Outcome
PremiumMarket NewsAstraZeneca Shares Fall on Lung Cancer Drug Trial’s Outcome
8d ago
Sophia Genetics announces collaboration agreement with AstraZeneca
Premium
The Fly
Sophia Genetics announces collaboration agreement with AstraZeneca
8d ago
J&J Rybrevant/Lazcluze study shows superiority over lazertinib for NSCLC
Premium
The Fly
J&J Rybrevant/Lazcluze study shows superiority over lazertinib for NSCLC
9d ago
Five AstraZeneca employees under investigation in China, Bloomberg reports
PremiumThe FlyFive AstraZeneca employees under investigation in China, Bloomberg reports
14d ago
C4 Therapeutics appoints Stephen Fawell to board of directors
Premium
The Fly
C4 Therapeutics appoints Stephen Fawell to board of directors
16d ago
AstraZeneca Shares and Voting Rights Update
Premium
Company Announcements
AstraZeneca Shares and Voting Rights Update
16d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100